April 18 (Reuters) - NEUROVIVE PHARMACEUTICAL AB:
* NEUROVIVE’S KL1333 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR TREATMENT OF MITOCHONDRIAL DISEASES
* ODD OPENS UP FOR MARKET EXCLUSIVITY FOR SEVEN YEARS WITHIN US FOR NEUROVIVE’S KL1333, WHEN AUTHORISED FOR MARKETING Source text for Eikon: Further company coverage: (Gdynia Newsroom)